Japan Foods for Special Medical Purposes for Infants Market Overview, 2031

Japan Foods for Special Medical Purposes for Infants Market Overview, 2031 Industry Ecosystem Analysis Japan’s foods for special medical purposes for infants ecosystem operates at the intersection of pediatric nutrition, infant formula manufacturing, hospitals and specialized food distribution. The country recorded 686,061 births in 2024, down 5.7% from the previous year, increasing the importance of specialized nutritional products for infants with congenital metabolic disorders, cow’s-milk-protein allergy and other medically managed nutritional needs. Meiji is a major domestic producer, reporting 20 special-milk products and 23.0 tonnes of supply in fiscal 2021, while Morinaga Milk maintains infant-formula production and develops formulas using hydrolyzed milk proteins and specialized oligosaccharides.

Patent & Innovation Landscape Innovation is focused on modifying protein structures, replacing problematic nutrients and improving digestibility while maintaining adequate infant nutrition. Meiji’s specialized formulas include hydrolyzed whey-protein products and an elemental formula using purified amino acids for infants who cannot tolerate conventional milk protein. The company reported 20 special-milk products in December 2022, covering registered, unregistered and commercially sold formulations. Such formulation development is particularly relevant to pediatric hospitals in Tokyo, Osaka and Fukuoka where medically supervised infant nutrition is required.

Recent Technology Trends The product pipeline is moving toward highly targeted nutritional formulations based on specific metabolic or allergic conditions. Japan’s National Center for Child Health and Development in Tokyo reported in February 2024 that the eliciting dose ED05 for cow’s milk among studied infants with food allergy was 6.1 mg of milk protein, equivalent to approximately 0.18 mL of milk, demonstrating the importance of precise allergen management. Specialized formulas therefore increasingly use extensively hydrolyzed proteins, amino-acid-based formulations and carefully controlled nutrient profiles.

Market Dynamics Market Driver: Specialized Nutrition Demand Medical conditions requiring specialized infant nutrition create demand that cannot be satisfied by standard formula alone. Meiji identifies congenital metabolic disorders and milk allergy among the conditions requiring special milk, with 20 products reported in its December 2022 portfolio. Japan’s 2024 birth count of 686,061 also means that even low-incidence metabolic and nutritional disorders translate into a continuing clinical requirement for specialized products supplied through hospitals, pharmacies and pediatric-care networks.

Market Challenge: Small Patient Population The market faces a structural volume constraint because many target conditions are uncommon and products often require specialized formulation, clinical oversight and controlled distribution. Meiji states that some congenital metabolic disorders occur at approximately one case per several tens of thousands of births, while its special-milk program supplied 23.0 tonnes in fiscal 2021. This creates a difficult balance between maintaining availability and achieving economically sustainable production volumes.



Market Trend: Personalized Infant Formula Condition-specific formulations are becoming more important as Japanese pediatric nutrition moves toward precise dietary management. Products can use hydrolyzed proteins, purified amino acids or modified nutrient compositions depending on the infant’s condition. Morinaga Milk’s E-Akachan, for example, uses highly digestible milk-protein peptides and three types of oligosaccharides, while Meiji markets an elemental formula based on purified amino acids for milk-allergic infants.

Regulatory Framework Japan classifies relevant products under the Foods for Special Dietary Uses framework. The Consumer Affairs Agency states that foods intended for special purposes including infant growth require permission for their special-purpose labeling from the Commissioner of the Consumer Affairs Agency under Article 43, Paragraph 1 of the Health Promotion Act. Government review also evaluates conformity with applicable standards and requirements before permission is granted.

Infant-formula nutritional specifications impose quantitative requirements. Japanese criteria specify 60–70 kcal per 100 mL for standard concentration, while protein is specified at 1.8–3.0 g per 100 kcal and fat at 4.4–6.0 g per 100 kcal. These requirements create a tightly controlled formulation environment for manufacturers supplying specialized infant products in Tokyo, Osaka and other Japanese healthcare markets.

Regulatory activity remained active during 2024 and 2025. The Consumer Affairs Agency granted permission for 2 special-purpose food items on December 11, 2024, followed by 2 items on January 8, 2025 and 3 items on March 7, 2025. The December 2024 revision also updated administrative requirements governing applications and labeling permissions for Foods for Special Dietary Uses.

Segment Analysis By Product Type The market includes extensively hydrolyzed formulas, amino-acid-based formulas, low-lactose products and formulas designed for specific congenital metabolic disorders. Meiji reported 20 special-milk products in December 2022, while its commercial portfolio includes hydrolyzed-protein and elemental formulas designed for infants requiring specialized nutritional management.

By Medical Condition Major categories include cow’s-milk-protein allergy, congenital metabolic disorders, lactose intolerance and other conditions requiring medically controlled nutrition. Meiji identifies congenital metabolic disorders and milk allergy as key indications, while the National Center for Child Health and Development’s 2024 research quantified cow’s-milk allergy thresholds among affected infants.

By Form Powdered formulas remain an important format, supported by established Japanese infant-formula manufacturing infrastructure, while liquid formulations provide an alternative where preparation convenience is important. Japan’s Foods for Special Dietary Uses framework explicitly covers both powdered and liquid infant formulas, providing regulatory recognition for the two formats.

By Distribution Channel Hospitals, pediatric clinics, pharmacies, specialized nutrition suppliers and direct commercial channels serve different product categories. Meiji notes that registered special milk is provided through a national assistance program, while commercially sold allergy formulas are available for medically managed infants, creating distinct institutional and retail pathways.

By End User Infants with medically diagnosed nutritional requirements represent the primary end-user group, with pediatric hospitals, clinics and caregivers acting as key decision-making participants. Tokyo’s National Center for Child Health and Development conducted 2024 infant allergy research involving children up to 12 months of age, illustrating the role of specialized pediatric institutions in identifying and managing dietary requirements.

Considered in this report
Historic Year: 2020
Base Year: 2025
Estimated Year: 2026
Forecast Year: 2031

Aspects covered in this report
Japan Foods for Special Medical Purposes for Infants Market with its value and forecast along with its segments
Various drivers and challenges
Ongoing trends and developments
Top profiled companies
Strategic recommendation

By Product Type

By Medical Condition

Major categories

By Form

Powdered formulas
Japan’s Foods for Special Dietary

By Distribution Channel

Meiji notes that registered special milk

By End User

Infants with medically diagnosed nutritional requirements